At the Annual General Meeting of Novo Nordisk A/S today, the
shareholders adopted the following resolutions:
* Adoption of the audited Annual Report 2006, including
approval of the remuneration of the Board of Directors.
* Resolution to distribute the profit according to the
adopted Annual Report 2006. The dividend will be DKK 7.00 per share
of DKK 2, an increase of 17% compared with 2005.
* Re-election of the following current board members elected
by the Annual General Meeting: Sten Scheibye, Göran A Ando, Kurt
Briner, Henrik Gürtler, Niels Jacobsen, Kurt Anker Nielsen and
Jørgen Wedel.
* Re-election of the auditor, PricewaterhouseCoopers.
* Resolution to reduce the Company's B share capital from
DKK 566,432,800 to DKK 539,472,800 by 13,480,000 B shares of DKK 2
each out of the Company's own holdings of B shares at a nominal
value of DKK 26,960,000, equal to 4% of the total share capital.
After completion of the share capital decrease, the Company's share
capital will amount to DKK 646,960,000 divided into A share capital
of DKK 107,487,200 and B share capital of DKK 539,472,800.
* Authorisation for the Board of Directors, until the next
Annual General Meeting, to allow the Company to acquire own shares
of up to 10% of the share capital and at the price quoted at the
time of the purchase with a deviation of up to 10%, cf Section 48
of the Danish Public Companies Act.
The Board of Directors
In February 2006, Novo Nordisk employees in Denmark elected four
board members: Johnny Henriksen, Anne Marie Kverneland and Stig
Strøbæk were re-elected and Søren Thuesen Pedersen was elected.
Accordingly the Board of Directors of Novo Nordisk A/S comprises:
* Sten Scheibye
* Göran A Ando
* Kurt Briner
* Henrik Gürtler
* Johnny Henriksen (employee representative)
* Niels Jacobsen
* Anne Marie Kverneland (employee representative)
* Kurt Anker Nielsen
* Søren Thuesen Pedersen (employees representative)
* Stig Strøbæk (employee representative)
* Jørgen Wedel.
For information on the board members, please refer to
novonordisk.com.
At a board meeting held immediately after the Annual General Meeting,
the Board of Directors constituted itself with Sten Scheibye as
chairman and Göran A Ando as vice-chairman.
The Board of Directors elected Kurt Anker Nielsen, Niels Jacobsen and
Jørgen Wedel as members of the Audit Committee with Kurt Anker
Nielsen as chairman. Kurt Anker Nielsen and Niels Jacobsen were
designated by the Board of Directors as Audit Committee Financial
Experts.
Finally, the Board of Directors designated Göran A Ando as Research
and Development facilitator.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. The company has the broadest diabetes product portfolio in the
industry, including the most advanced products within the area of
insulin delivery systems. In addition, Novo Nordisk has a leading
position within areas such as haemostasis management, growth hormone
therapy and hormone replacement therapy. Novo Nordisk manufactures
and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and
society. With headquarters in Denmark, Novo Nordisk employs more than
23,600 employees in 79 countries, and markets its products in 179
countries. Novo Nordisk's B shares are listed on the stock exchanges
in Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Mike Rulis Mads Veggerby Lausten
Tel: (+45) 4442 3573 Tel: (+45) 4443 7919
mike@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Lori Moore Christian Qvist Frandsen
Tel: (+1) 609 919 7991 Tel: (+1) 609 919 7937
lrmo@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 7 / 2007